Weight-loss patients may soon have access to more GLP-1 treatments as Eli Lilly confirmed the local regulator was evaluating its new oral obesity drug, orforglipron, which a recent study showed was ...
MHRA disrupts second manufacturing facility UK law enforcement officers raided two separate premises containing illegal weight loss medicines.1 Medicines and Healthcare Products Regulatory Agency ...
The FDA’s effort to crack down on compounded versions of popular GLP-1 weight-loss drugs has sparked backlash from patients and compounding pharmacies over concerns about access and ...
A new oral version of the weight loss drug Wegovy has been approved by the FDA, offering a more affordable and accessible ...
GLP-1s were first approved in 2005 for the treatment of Type 2 diabetes. Since then, more versions of the medication have hit the market, becoming more accessible to patients and used for a wider ...
Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...
Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.
Researchers have hailed a new once-a-day weight loss pill as an “important advancement” in type 2 diabetes care. A new study ...
The newly-approved device requires only that patients swallow it in their doctor's office to achieve weight loss, according ...
Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.
An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared ...
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results